Abstract
In this chapter we will discuss experiences with randomised controlled trials (RCTs) in the acute treatment of migraine. With the introduction of the new 5-hydroxytryptamine (5HT)1B/1D receptor agonist sumatriptan [1], the first drug developed specifically for migraine, and recently other triptans, the focus in RCTs in migraine has overwhelmingly been on acute migraine treatment. Only one prophylactic drug, the antiepileptic drug sodium valproate, has been introduced in recent years [2–5]. This chapter is based partly on our personal experience with multicenter RCTs in acute migraine treatment (n = 6) in recent years, partly on what we have perceived as problems in published multicenter RCTs. More systematic reviews on RCTs in migraine therapy are available [5–17].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
